Novelty & Impact Statement: This study demonstrates that appropriate delivery of the culinary agent, curcumin, to glioblastoma brain tumors (GBM) causes a dramatic repolarization of tumor-associated microglia from a population of tumor-promoting M2-type microglia to a milieu of tumoricidal M1-type microglia and tumor remission in 50-60% of GBM-harboring mice. Our findings usher in the promise of changing the mainstream tumor therapy, thereby instilling immense hope in brain tumor patients most of whom currently surrender themselves to palliative care.
Introduction
In recent years, curcumin (CC), a plant-derived polyphenol and the coloring component of the culinary spice turmeric has generated considerable interest by proving to be a strong anti-cancer agent against a wide range of cancer cells while being non-toxic normal cells [1] [2] [3] . Yet, presumably due to its low bioavailability in vivo, curcumin has found little clinical use in treating cancer. Among multiple strategies designed by us to boost the in vivo efficacy of CC, antibody targeting of CC to cancer cells in the brain has shown great promise 4, 5 . In our prior studies, we targeted the food-derived anti-cancer agent curcumin (CC) to the mouse GBM cells GL261 and orthotopic GBMs by linking it through a cleavable ester bond to an antibody (Ab) against CD68, which is expressed highly by GBM cells and at a lower level by microglia 5 . Although this strategy increased the potency of CC by two to three orders of magnitude, delivering the antibody-CC adduct into the brain remained as a formidable challenge. Here, we show that intranasal (IN) delivery of the Ab-CC adduct overcomes this hurdle, thereby rescuing mouse glioblastoma GL261-implanted mice. Additionally, a commercially available lipid-complexed form of curcumin (Curcumin Phytosome-Meriva) also proved to be highly effective even when delivered intraperitoneally (i.p.). However, it is not clear if the efficacy of appropriately delivered curcumin is only due to its ability to kill cancer cells. The current study addresses this question and identifies an activity of CC that may contribute greatly to its ability to eliminate established tumors in the brain 4, 5 .
Earlier reports indicate that many plant-derived food items stimulate our immune system 2, 6 . It is also known that several gene mutations can trigger carcinogenesis 7 , and cancer is prevented if such aberrantly generated cells are eliminated by a vigilant immune system. Thus it is likely that plant-derived foods play an important role in stimulating our immune system to eliminate cancer cells. Curcumin regulates the activity of T-cells in the peripheral immune system and also the macrophages [8] [9] [10] . Although the brain is not expected to harbor the complete battery of lymphocytes and the complement system of the peripheral tissue, it has been shown to harbor microglia, which in their pro-inflammatory M1 state serve as antigen-presenting immune cells that are known to kill cancer cells [10] [11] [12] [13] [14] . Here we demonstrate that appropriately delivered CC directly kills
Drug treatments and determination of IC50: Aliquots of CC-CD68 Ab and curcumin phytosome (CCP)
were suspended in the required volume of medium (serum-free RPMI with 1% ITS supplement for GL261 and stem-pro medium for GBM994, GBM46, and GBM6 cells), serially diluted in the respective medium to generate a series of working concentrations, which were tested in vitro on GL261, GBM994, GBM46 and GBM6 cells to determine the cytotoxic potency of the two curcumin derivatives. The cells were treated with drugs when the wells reached 30-40% confluence. Cells were visually monitored for degeneration (membrane blebbing and degradation) 48 hours after treatment by light microscopy. After 96 hours of treatment, the medium in each well was aspirated, and the cells were gently rinsed three times with PBS. Next, the cells were incubated at 37 °C for 45 min with 10% WST-1 (v/v) (Clontech, Mountain View, CA) diluted in serum-free DMEM (v/v) as described in our earlier report 5 , and the absorbance of the resultant solution monitored at 440 nm using a plate reader. Dose dependent response curves were generated from the absorbance to determine the IC50 of the drugs for all the brain tumor cell lines. Microsoft Excel was used for graphical analysis.
Preparation of Dylight 800-CD68 Ab and curcumin-CD68 Ab adducts: (Please see Supplementary
Information). The curcumin:Ab ratio in the CC-CD68Ab adduct was determined by spectroscopy and also MALDI-TOF as 1:1 (Supplementary Figure 1) .
Implantation of cancer cells in mice: (Please see Supplementary Information).
Intranasal delivery of the curcumin-CD68 Ab adduct and intra-peritoneal delivery of Curcumin phytosome on GL-261 implanted mice: In a pilot experiment, we used a mouse implanted with 80,000 GL261 cells. From day 11 after the implantation, intranasal application of vehicle (30 µl sterile 10 mM PBS) was conducted every 72 hours intranasally as described for CC-CD68 Ab application in the larger experiments.
For the larger experiments using mice implanted with 10 5 GL261 cells, on the tenth day after implantation, the mice were anesthetized, placed in the supine position, and 120 pmoles of CC-CD68 Ab adduct (CC:Ab: 1:1) (containing 18 µg of CD68 Ab) dissolved in 30 µl of sterile 10 mM PBS was applied as 3-µl drops using a micropipette, alternately, every two minutes, to each nostril and allowed to be snorted in.
We also used a commercially available product, Curcumin Phytosome featuring Meriva (CCP) 17 Post-mortem brain examination by ex vivo near-IR scanning: When the mouse in the pilot experiment appeared morbid, it was anesthetized and then 30 µl of the DyLight-800-CD68 Ab adduct in 3-µl aliquots was administered, every two minutes, to alternate nostrils while holding the mouse in the supine position. Six hours after administration, the mouse was sacrificed, the brain removed and fixed in 4% paraformaldehyde. Near-IR images were acquired using the Odyssey® Imaging System (LI-COR Biosciences, Nebraska). Brightfield images were acquired using a using a digital camera. The Dylight-800 fluorescence is pseudocolored green and the enhanced autofluorescence of the brain tissue (~ 700 nm, autofluorescence) was pseudocolored red. microscope from multiple randomly chosen fields encompassing regions in and around the tumor and scartissue region (Fig. S4) . ImageJ was used to obtain the iNOS, arginase1, p65 (NF-kB), P-Ser 276 -p65, STAT-1, PTyr 701 -STAT1 and HOECHST33342 fluorescence intensity. The fluorescent intensity of all the abovementioned antibodies were normalized to HOECHST33342 intensity (blue). Since p65 NF-kB and STAT1
displayed both induction as well as phosphorylation-mediated activation, the HOECHST-normalized staining intensities were expressed both as P-p65 NF-kB/p65 NF-kB and P-STAT1/STAT1 as well as P-p65 NFkB/HOECHST and P-STAT1/HOECHST.
Flow cytometry of immunostained brain tumor and scar tissue cells:
The brains from the GL-261
implanted, morbid mice (vehicle-treated control mice) and the rescued mice (GL261 implanted, curcumin derivative treated mice living more than 120 days) were extricated without fixing (after anesthesia), and rinsed twice with PBS. Next, only the cells from the tumor area (vehicle-treated) (the tumor core, periphery and most area around it) and scar tissue area (curcumin treated, rescued) (scar tissue core, periphery and most area around it) from these unfixed brains were dissociated by mild trypsinization using 0.25% trypsin-EDTA and repeated gentle trituration using a fire-polished Pasteur pipette to generate single cell suspensions [18] [19] [20] . The cells were filtered through a sieve to remove clumps and fixed using freshly made 4% para-formaldehyde (PFA). The fixed cells were counted and stored in PFA at 4 °C. Around 2 million fixed cells from each animal were used for immunostaining as described under immunocytochemistry. After each antibody treatment, the cells were pelleted down and resuspended in washing buffers. Antibodies against Iba1 (C20) (1:200), iNOS (1:200) and Arginase1 (1:200) were used for staining. Secondary antibody-treated cells were used to set the threshold.
Flow cytometry was performed using Accuri C6 flow cytometer (BD). For each sample, events above 10 4 forward and 10 3 side scatter were gated, and 100,000 gated events were analyzed. After compensation of fluorescent events to minimize the spillover from each channel, subpopulations of cells appeared in different quadrants based on their fluorescence intensities. Events from autofluorescence and non-specific fluorescence from the "2° antibody only" samples appeared as a distinct population in the lower-left quadrant (LL quadrant).
The double-stained fluorescent events from ARG1+, Iba1+ or iNOS+, Iba1+ cells appearing as sub-populations in the upper right (UR) quadrant within the coordinates 520 nm (green for ARG1 and iNOS) (FL1-A) and 580 nm (red for Iba1) (FL2-A) were considered and mean fluorescence intensity was measured using the mean method of statistical analysis per double-stained cell.
Hematoxylin and eosin (H&E) staining of tissue sections: (Please see Supplementary Information).
Statistical analysis: Two-tailed t-tests with unequal variance were used while comparing the two groups, vehicle-treated and CC-treated and rescued, and p ≤ 0.05 was considered as significant.
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Results

CD68 expression in patient-derived GBM explant cells and IC50 for targeted curcumin in the CC-
CD68Ab adduct. In our prior reports we had shown that CD68, an antigen expressed at a low level by microglia is highly expressed by the mouse glioblastoma GL261 cells, and targeting of CC in a releasable form using a CD68 antibody causes a 125-fold decrease in the IC50 of CC in eliminating GL261 cells 5 . Here we investigated the cellular localization and the levels of expression of CD68 in three patient-derived GBM cell lines. We wanted to investigate if the levels of cell-surface expression of CD68 did in any way influence the IC50 value for CC-CD68 Ab. As shown in (Fig. 1a) , the GBM6 cells expressed lower levels of cell surface and higher levels of nuclear CD68. This was also associated with a higher IC50 for CC-CD68 Ab (still in the nanomolar range-300 nM-indicating much higher potency than free CC), suggesting that less cell-surface antigen molecules were available for antibody binding. Our earlier studies have also shown that the targeting antibody without the attached CC molecules does not kill targeted cells 4 and also that the CD68Ab-CC is taken up by the GL261 cells, thereby causing CC release inside (marked by an increase in fluorescence due to CC) and destruction of the targeted cell 5 . Among the three patient-derived GBM cells, GBM994 displayed the highest sensitivity to CC-CD68 Ab. Whereas free curcumin eliminated the GBM994 cells with an IC50 of 22.5
µM, the IC50 of targeted-CC (CC-CD68 Ab) was 800-fold lower (25 nM) (Fig. 1b and c) . Our MALDI-TOF analysis showed that one molecule of CC was linked to one Ab molecule in the adduct ( Fig. S1a and b) , which enabled us to calculate the concentration of Ab-linked curcumin for all treatments. Lack of staining with the secondary antibody alone (Fig. S2) confirms that the CD68 staining was specific.
Based on the curcumin content of CCP, this lipid-complexed preparation of CC was able to eliminate GL261 cells with an IC50 of 15 µΜ, which was similar to the IC50 observed for free curcumin for the GL261 cells in culture ( Figure S3 ) 5 .
Intranasal delivery of CC-CD68Ab conjugate and CCP both cause elimination GL261 GBM brain tumor and rescue of mice. In a pilot experiment, a Gl261-implanted mouse was allowed to proceed to morbidity ( Fig. 2a) and then anesthetized for intranasal (IN) delivery of the CD68 Ab linked to a near-infrared (Near-IR) dye Dylight800 as illustrated in Fig. 2b . The antibody-dye conjugate reached the brain and accumulated in the GBM, the location of which was detected by both near-IR scanning and also bright-field imaging ( Fig. 2c and   d ). This confirmed that the CD68Ab could be delivered to the brain via the IN route. In our earlier studies, free curcumin, administered through the tail vein, was able to reach the brain within fifteen minutes 1 , but the transient level of curcumin achieved in the brain through this route was not sufficient to bring about a rescue of the tumor cell-implanted mice 4 . To test if the lipid-complexed preparation, CCP, was capable of producing an effect on GBM, we suspended 2 mg this solid (CCP) in 200 µl sterile PBS and injected this translucent emulsion per mouse (i.p.) from day 10 after implantation of 100,000 GL261 cells per mouse on day 1. In parallel, GL261-implanted mice were also i.p. injected with PBS (vehicle-treated). Such i.p injection of CCP but not vehicle every 72 hours for one month was able to rescue 60% of the GL261-implanted mice (Fig. 2e) .
In parallel, CC-CD68Ab adduct was administered IN every 72 hours from day 10 after Gl261 implantation.
Adduct treatment (120 pmole per mouse, per treatment) every 72 hours four times and then once every seven days (four times) caused remission of GBM in 50% of the GL261-implanted mice (Fig. 2e) . Thus, both strategies for curcumin delivery seem to be highly effective for GBM therapy.
We identified the tumor and scar tissue areas along with the surrounding areas by H&E staining in parallel brain sections ( Figure S4 ) and then used the above-mentioned areas from adjacent sections for our subsequent analyses. Being cognizant of CC's tumoricidal ability from our previous study 4, 5 , we investigated the presence of tumor (CD68 high ) cells at the tumor core of the vehicle-treated mice (Fig. S4A ) and the scar tissue area (Fig.   S4B ) of the CC-treated and rescued mice. As expected, the tumor core had a plethora of CD68 high tumor cells, 23 . Immunohistochemistry (IHC) analysis of GBM sections revealed that the GBM tumors and the surrounding areas (Fig. S4A) contained a large number of Iba1+ microglia, which also expressed high levels of ARG1 (Fig. 3a) . In sharp contrast these sections expressed very low levels of inducible nitric oxide synthase (iNOS), which is highly expressed by the M1-type microglia 24 ( Fig. 3A) .
Next, we analyzed the relative expression of ARG1 and iNOS by Iba1+ cells present in the scar tissue and the surrounding areas (shown within a circle in Fig. S4B ) in the brains of the rescued mice. A dramatic decrease in ARG1 along with a striking increase in iNOS expression was observed in Iba1+ cells contained within the scar tissue region (Fig. 3B and C) . Normalization of the staining intensity of ARG1 or iNOS to that for HOECHST (nuclear staining) and quantification from random fields of multiple mouse brains confirmed that CC treatment and rescue was associated with an 85.1% (6.71-fold) decrease in ARG1 along with a 206.3% (3.06-fold) increase in iNOS in the 1ba1+ microglia ( Fig. 3D and E) .
The specificity of the primary antibodies was confirmed by the lack of staining with the secondary antibodies alone (Figure S7 ).
Flow cytometry analysis in GBM or scar tissue indicates that discrete populations of Iba1+ microglia are affected during CC treatment and rescue. Based on the observed immunohistochemistry results, flow cytometry analysis was performed on cells dissociated from vehicle-treated tumor areas (Fig. S4A) and CCtreated and rescued scar tissue areas marked a circle in Fig. S4B . The dissociated cells were fixed in 4%
formaldehyde, permeabilized with 0.1% Triton X-100, divided into multiple aliquots, and then individual aliquots of cells immunostained using antibodies against ARG1 and Iba1 or iNOS and Iba1. For each sample, events above 10 4 forward and 10 3 side scatter were gated, and 100,000 gated events were analyzed (Fig. 4A, F) .
Fluorescence from the 2° Ab-treated cells was used to mark the threshold (10 4 for FL1-A at 520 nm (green) and Fig. 4B, C, G, H) . From these double-positive populations, the total fluorescence intensity from all the cells was recorded (Fig. 4D, I ) and mean fluorescence per cell was used for quantification (Fig. 4E,J) . While the Iba1+ cells in the tumor area were ARG1 high , iNOS low in the vehicle-treated mice, in the scar tissue area of the rescued mice the Iba1+ cells were ARG1 low , iNOS high (Fig. 4E, J) . These changes were 69.58% (a 3.28-fold decrease) for ARG1 and 154% (2.54-fold increase) for iNOS (Fig. 4E, J) .
The mean Iba1 fluorescence per double-stained cell (ARG1+ or iNOS+) was also significantly different between the two groups. While the Iba1 fluorescence intensity per cell in the ARG1+ cells in the scar tissue area of the rescued mice was 73.92% (3.83-fold) less than in the tumor area of the vehicle-treated mice, the Iba1 fluorescence in the iNOS+ cells in the scar tissue area was 184% (2.84-fold) higher than in tumor area of the vehicle-treated mice (Fig. 4L) . Thus, CC treatment caused a parallel decrease in both ARG1 and Iba1 fluorescence and a parallel increase in iNOS and Iba1 fluorescence in the double-stained TAMs. However, the mean Iba1 intensity did not significantly differ between the two groups (iNOS+,Iba1+ and ARG1+, Iba1+ cells) (Fig. 4M) . This supported the possibility that CC treatment was responsible for the silencing of one group of ARG1+ TAMs and the parallel activation of a separate set of iNOS+ TAMs.
CC-treated and rescued mice show a sharp induction and activation of NF-kB (p65) and STAT1 in the
Iba1+ microglia. Earlier studies performed in macrophages posit that co-stimulated NF-kB (p65) and STAT1
cooperate by binding to appropriate enhancer elements to activate the iNOS gene 25, 26 . To effect such a change, CC treatment should cause activation of both of these two transcription factors in the tumor-associated microglia.
As expected, the Iba1 + cells in the scar tissue of the CC-treated and rescued mice showed an 85% (1.85-fold) increase in activated p65 NF-kB (P-Ser 276 -p65 normalized to total p65 NF-kB) compared to that in the tumor sections (Fig. 5A, B, C) . In parallel, a 300% (4-fold) increase in p65 expression was observed in the Iba1+ scar tissue TAMs (Fig. 5D) , which resulted in a net increase in 642% (7.42-fold) in P-p65 NF-kB in the scar tissue TAMs over that in the tumor TAMs in the vehicle-treated mice (Fig. 5E) .
Similarly, the Iba1 + cells in the scar tissue from the CC-treated and rescued mice showed a 591% (6.9-fold) increase in activated STAT1 (P-Tyr 701 -STAT1 normalized to total STAT1) (Fig. 6A, B, C) . In parallel, a 652% (7.52-fold) induction in STAT1 was observed (Fig. 6 A, B, D) , which resulted in a net increase of 5134%
(52.34-fold) in activated (P-STAT1) in the CC-treated and rescued mice (Fig. 6A, B 
, E).
The activated p65 (NF-kB) and STAT1 were co-localized in the same Iba1+ microglia in both tumorassociated and scar tissue-associated TAMs (Fig. S6) . The specificity of the primary antibodies was confirmed by the lack of staining with the secondary antibodies alone (Fig. S7) .
Discussion
As revealed by the sheer number of publications, the polyphenolic plant-derived food product CC has generated immense interest in the recent years. Its strong activity against a wide range of cancer cells and also its beneficial effects in mouse models for Alzheimer disease and cardiac hypertrophy have, at the very least, established its importance in health sciences [27] [28] [29] . However, the lack of significant outcomes in human clinical trials has considerably dampened the interest in CC as a future therapeutic agent [30] [31] [32] [33] [34] [35] . Our group has persistently argued that such failures are due to its low bioavailability and that an improved design of delivery would resurrect CC as a promising therapeutic agent 4, 5, 36 . As opposed to the delivery of toxic agents or radioisotopes specifically to the cancer cells [37] [38] [39] [40] , appropriate delivery of CC could overcome its poor bioavailability and also serve the function of stimulating the body to fight the residual cancer cells.
With such dual objective we used two strategies, one to deliver CC in a commercially available phytosome-complexed form that is already consumed as a supplement 17 , and the other to deliver CC linked to a GBM-specific antibody. In the second strategy, we linked curcumin to a CD68 antibody through an ester bond that would be cleaved by intracellular esterases. This would target CC mainly to the CD68-loaded GBM cells and also direct it to the tumor-associated microglia that express lower levels of surface CD68 5 . The central idea was that the large antibody molecule would solubilize, protect, and quickly deliver the CC molecules to GBM.
Next, the CC released from the CC-CD68Ab molecules that are taken up by endocytosis by the GBM cells would kill these cells. Additionally, some CC-CD68Ab molecules that are targeted to and taken up by GBMassociated microglia would be expected to stimulate these cells to release cytokines to kill the GBM cells and then eliminate the dead cells through phagocytosis. However, this would require CC-mediated alteration of the tumor-associated microglia population from the tumor-promoting M2 to the tumoricidal M1 state [9] [10] [11] [12] [13] [14] .
To analyze the cells of the microglial lineage, we first used IHC and then flow cytometry to identify and quantify the expression of ARG1 or iNOS in cells that coexpressed Iba1. This could not be achieved by
Western blotting, because ARG1 and iNOS are also expressed by other cell types and tumor cells that do not express Iba1 and the whole tumor or scar tissue would yield ARG1 and iNOS profiles that may not be linked to the microglia. The overall repolarization was evident from both IHC and flow cytometry. Based on both immunohistochemistry and flow cytometry, in the CC-treated and rescued mice, we observed a 154-205% increase in iNOS fluorescence along with a concomitant 69.58-85% decrease in ARG1 fluorescence in the Iba1+ microglial cells (Fig. 3 and 4) . Since Iba1 is the signature of the activated microglia 21, 22 , the results indicate that in the CC-treated mice, the tumor-associated ARG1 high , Iba1+ M2 microglial populations are suppressed while a discrete population of iNOS high , Iba1+ M1-type microglia is activated in the CC-treated and rescued mice. Alternatively, M1-type macrophages, which are also identified by Iba1 staining, could be recruited into the brain from the peripheral system 41 . Interestingly, the overall Iba1 intensity for both iNOS high /Iba1 + and ARG1 high /Iba1 + cells between vehicle treated and CC-rescued mice remained unchanged, indicating that the number of M2-TAMs (vehicle group) was approximately equal to the number of M1 TAMs (CCtreated) (Fig. 4) . Thus, CC-evoked tumor elimination (Fig. S4 and 5 ) may involve suppression of these tumorpromoting and immunosuppressive M2-TAMs along with concomitant activation and/or recruitment of tumorcidal M1 TAMs.
Although our results demonstrate that following appropriate delivery, CC in both CCP and CC-CD68Ab brings about tumor remission in 50-60% of mice harboring established brain tumors, it is not clear why the remaining 40-50% mice were not rescued (Fig. 3) . A likely reason was that the immune system of each mouse was discretely responsive to CC treatment. Our current experiments are addressing this question.
The mechanistic underpinnings of this CC-evoked switch in brain microglia/macrophage population may invoke some debate. Previous in vitro studies performed mainly on peripheral macrophages have shown that the non-classical M2 mode of activation of tumor-associated macrophages involves the stimulation of the transcription factor STAT3, which triggers induced ARG1 expression and blocks STAT1 activation 42, 43 . CC is known to inhibit STAT3 in in vitro and in vivo studies performed in tumor-associated macrophages 10, 44 . STAT3 triggers the release of immunosuppressive factors, such as IL-6 and IL-10 from tumor cells 45 , and IL-10 in turn blocks interferon-gamma-mediated STAT1 activation 46 . Thus, it is expected that in the GBM-harboring mice, CC treatment would be linked to STAT3 inhibition and removal of the STAT3-IL-10-mediated block of STAT1 activation. Therefore, based on earlier observations in tumor-associated macrophages, it is expected that CC treatment of the GBM-harboring mice would cause an increase in the level of active STAT1 (P-Tyr 701 -STAT1) in the 'resting' scar tissue microglia in the rescued mice, causing activation, proliferation and/or recruitment of the tumorcidal M1 microglia/macrophages. Corroboratively, we observed a dramatic increase in activated STAT1 (P-Tyr 701 -STAT1) in the Iba1+ microglia/macrophages in the CC-treated and rescued mouse brains (Fig. 6) .
Concomitantly, we also observed a striking increase in activated NF-kB (P-Ser 276 -p65) in the Iba1+ scar tissue microglia (Fig. 5) . Heterodimeric p50/pp65 NF-kB activation as measured by an increase in P-Ser 276 -p65, has been linked to the activation of M1-type macrophages, and tumor-associated macrophages have been shown to display alternative macrophage activation to the M2 phenotype through nuclear localization of the NF-kB p50-homodimer 47 . By analogy, the increased presence of P-Ser 276 -p65 in the CC-treated GBMassociated Iba1+ microglia ( (n = 10) and CC-CD68Ab (n = 8) caused 50% or higher rescue of GL261-implanted mice, whereas all PBStreated mice succumbed to GBM (n = 10). 
. (B-E)
The CC-treated, rescued mice showed an 85% (1.85-fold) increase P-p65 NF-kB with respect to p65 NF-kB (B, C), a 300% (4-fold) induction in p65 NF-kB, thus resulting in (E) a 642% (7.42-fold) overall increase in P-p65 NF-kB relative to that in vehicle-treated tumor tissue. Five sections per mouse were used for imaging and data were graphically presented as mean ± SEM.).
Scale bar: 47.62 µm. .62 µm The activated P-p65 NF-kB and P-STAT1 molecules were co-localized in the same Iba1+ microglia in the scar tissue-associated TAMs (Fig. S6) . The specificity of the primary antibodies was confirmed by the lack of staining with the secondary antibodies ( Figure S7 
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